O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
Titel:
O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
Auteur:
Wainberg, Z. Melisi, D. Macarulla, T. Cid, R. Pazo Chandana, S. Fouchardière, C. de la Dean, A. Kiss, I. Lee, W. Goetze, T. Van Cutsem, E. Paulson, S. Bekaii-Saab, T. Pant, S. Hubner, R. Xiao, Z. Chen, H. Benzaghou, F. O'Reilly, E.